{"id":"W4296202942","doi":"10.1016/j.jtocrr.2022.100408","title":"A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Helix Biopharma (Canada)","funders":"","keywords":"Medicine; Carboplatin; Tolerability; Pemetrexed; Rash; Internal medicine; Adverse effect; Neutropenia; Febrile neutropenia; Dosing; Loading dose; Oncology; Gastroenterology; Pharmacology; Urology; Toxicity; Chemotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00401454,0.0001311079,0.0005318563,0.0001928892,0.0001519315,0.00002777809,0.0001181564,0.00004279125,0.00009530497],"category_scores_gemma":[0.001006346,0.0000852965,0.00001843702,0.001274053,0.0002161959,0.00009661741,0.0002218701,0.0009464382,4.917082e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001605046,"about_ca_system_score_gemma":0.0004689268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002511053,"about_ca_topic_score_gemma":0.0001999427,"domain_scores_codex":[0.9963043,0.0005466293,0.001048787,0.0005458099,0.00128316,0.0002713101],"domain_scores_gemma":[0.9981243,0.0006544893,0.0002741547,0.000372856,0.0003457085,0.0002284876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04515731,0.127194,0.7945217,0.0003926442,0.0001624893,0.002287478,0.001161272,0.0001444797,0.0003180114,0.00003867394,0.0001986314,0.02842326],"study_design_scores_gemma":[0.1826577,0.06239525,0.7393346,0.0003363323,0.0001937227,0.00006963471,0.003685707,0.009379022,0.0002575027,0.0001397867,0.001175479,0.0003752121],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952567,0.00003736958,0.000008915657,0.0003756018,0.00002806556,0.003949753,0.0000175383,0.00001028161,0.0003158074],"genre_scores_gemma":[0.998534,0.0000138892,0.0002184052,0.00002322225,0.00001340354,0.0006525877,0.00009468057,0.0000158957,0.0004339353],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1375004,"threshold_uncertainty_score":0.4111856,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2669794915815009,"score_gpt":0.5310140040131872,"score_spread":0.2640345124316864,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}